Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

17.69 +0.01 (+0.06%)
Streaming Delayed Price Updated: 10:00 AM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Lyft, BARK And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
HUTCHMED to Announce 2022 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
Via Benzinga
Hutchmed Plans Strategic Focus Shift On Late-Stage Programs, Details Not Disclosed
Via Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development... 
Via Benzinga
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Constellation Brands, Walgreens, RPM International And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
From Prenetics Limited
Via GlobeNewswire
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. 
Via Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing
Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Miniso Group, Monday.com And Other Big Gainers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study
HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning! 
Via InvestorPlace
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.